5-lipoxygenase-activating protein

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Arachidonate 5-lipoxygenase-activating protein
5lip.png
Crystallographic structure of the inhibitor-bound human 5-lipoxygenase-activating protein.[1]
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols ALOX5AP ; FLAP
External IDs OMIM603700 MGI107505 HomoloGene1231 ChEMBL: 4550 GeneCards: ALOX5AP Gene
Orthologs
Species Human Mouse
Entrez 241 11690
Ensembl ENSG00000132965 ENSMUSG00000060063
UniProt P20292 P30355
RefSeq (mRNA) NM_001204406 NM_009663
RefSeq (protein) NP_001191335 NP_033793
Location (UCSC) Chr 13:
31.31 – 31.34 Mb
Chr 5:
149.27 – 149.29 Mb
PubMed search [1] [2]


Arachidonate 5-lipoxygenase-activating protein also known as 5-lipoxygenase activating protein, or FLAP, is a protein that in humans is encoded by the ALOX5AP gene.[2][3]

Function[edit]

FLAP is necessary for the activation of 5-lipoxygenase and therefore for the production of leukotrienes.[4] It is an integral protein within the nuclear membrane. FLAP is necessary in synthesis of leukotriene, which are lipid mediators of inflammation that is involved in respiratory and cardiovascular diseases. FLAP functions as a membrane anchor for 5-lipooxygenase and as an amine acid-bind protein. How FLAP activates 5-lipooxygenase is not completely understood, but there is a physical interaction between the two. FLAP structure consist of 4 transmembrane alpha helices, but they are found in 3’s( trimer) forming a barrel. The barrel is about 60 A high and 36 A wide.[1]

Clinical significance[edit]

Gene polymorphisms in FLAP are suspected of playing a role in Alzheimer's disease.[5] Leukotrienes, which need the FLAP protein to be made, have an established pathological role in allergic and respiratory diseases. Animal and human genetic evidence suggests they may also have an important role in atherosclerosis, myocardial infarction, and stroke. The structure of FLAP provides a tool for the development of novel therapies for respiratory and cardiovascular diseases and for the design of focused experiments to probe the cell biology of FLAP and its role in leukotriene biosynthesis.[1]

Inhibitors[edit]

References[edit]

  1. ^ a b c PDB 2q7r; Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW (July 2007). "Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein". Science 317 (5837): 510–2. doi:10.1126/science.1144346. PMID 17600184. 
  2. ^ Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA (May 1991). "Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP)". J. Biol. Chem. 266 (13): 8511–6. PMID 1673682. 
  3. ^ Yandava CN, Kennedy BP, Pillari A, Duncan AM, Drazen JM (February 1999). "Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12". Genomics 56 (1): 131–3. doi:10.1006/geno.1998.5651. PMID 10036194. 
  4. ^ Peters-Golden M, Brock TG (2003). "5-lipoxygenase and FLAP". Prostaglandins Leukot Essent Fatty Acids 69 (2-3): 99–109. doi:10.1016/S0952-3278(03)00070-X. PMID 12895592. 
  5. ^ Manev H, Manev R (2006). "5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease". Med Hypotheses 66 (3): 501–3. doi:10.1016/j.mehy.2005.09.031. PMID 16278051. 
  6. ^ Musiyenko, A.; Correa, L.; Stock, N.; Hutchinson, J. H.; Lorrain, D. S.; Bain, G.; Evans, J. F.; Barik, S. (2009). "A Novel 5-Lipoxygenase-Activating Protein Inhibitor, AM679, Reduces Inflammation in the Respiratory Syncytial Virus-Infected Mouse Eye". Clinical and Vaccine Immunology 16 (11): 1654. doi:10.1128/CVI.00220-09. PMC 2772391. PMID 19759251.  edit

Further reading[edit]

External links[edit]